AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Five brokerages give AngioDynamics a consensus rating of Moderate Buy (1 sell, 3 buy, 1 strong buy) with an average 1‑year target price of $19.33.
• Shares opened at $10.90, the company has a market cap of $449.3 million and a negative P/E of -16.27, with a 1‑year trading range of $8.36 to $13.99.
• Institutional investors own about 89.43% of the stock, and several funds recently initiated or increased small positions.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $19.3333.

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of AngioDynamics from a "buy" rating to a "hold" rating in a report on Sunday, December 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Zacks Research raised AngioDynamics from a "hold" rating to a "strong-buy" rating in a report on Friday, January 9th.

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue purchased a new position in shares of AngioDynamics in the 3rd quarter valued at $25,000. Farther Finance Advisors LLC boosted its stake in AngioDynamics by 146.4% in the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 1,199 shares in the last quarter. Washington Trust Advisors Inc. acquired a new position in AngioDynamics in the third quarter valued at $27,000. Kemnay Advisory Services Inc. acquired a new stake in shares of AngioDynamics in the 4th quarter valued at about $27,000. Finally, State of Wyoming purchased a new position in AngioDynamics during the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $10.90 on Friday. The company has a market cap of $449.30 million, a price-to-earnings ratio of -16.27 and a beta of 0.48. The stock's 50-day moving average is $10.80 and its two-hundred day moving average is $11.54. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.